Stephen Harrison, MD: Resmetirom Could Address 'Monumental'

Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.

Related Keywords

Stephen Harrison , A Stephen Harrison , Madrigal Pharmaceuticals Announces , Madrigal Pharmaceuticals Announces Publication Of The Phase , Pinnacle Clinical Research , Madrigal Pharmaceuticals , Drug Administration , Priority Review , Madrigal Pharmaceutical New Drug Application , New England Journal , New Drug Application , Madrigal Pharmaceuticals Announces Publication , Promising Phase , Nafld , Nonalcoholic Fatty Liver Disease , Nash , Nonalcoholic Steatohepatitis , Pdufa , Thyroid , Fatty Liver , Metabolic Dysfunction Associated Steatohepatitis , Resmetirom ,